Katie Beal, MD | |
2900 Medical Center Pkwy Ste 240a, Bentonville, AR 72712-3204 | |
(479) 553-3340 | |
(479) 553-1964 |
Full Name | Katie Beal |
---|---|
Gender | Female |
Speciality | Obstetrics & Gynecology |
Location | 2900 Medical Center Pkwy Ste 240a, Bentonville, Arkansas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558709469 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 2013017461 (Missouri) | Secondary |
207V00000X | Obstetrics & Gynecology | E-10369 (Arkansas) | Primary |
Entity Name | Northwest Benton County Physician Services Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871553073 PECOS PAC ID: 3577503689 Enrollment ID: O20050509000505 |
News Archive
Researchers from the Duke Human Vaccine Institute and Duke University, Durham NC, USA, recently analyzed the D614G mutation in SARS-CoV-2 in the context of a soluble S ectodomain construct. Their study has been published in the preprint server bioRxiv.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.
Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union.
› Verified 6 days ago
Entity Name | Lifespring Women's Healthcare Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164519450 PECOS PAC ID: 1254332083 Enrollment ID: O20070123000090 |
News Archive
Researchers from the Duke Human Vaccine Institute and Duke University, Durham NC, USA, recently analyzed the D614G mutation in SARS-CoV-2 in the context of a soluble S ectodomain construct. Their study has been published in the preprint server bioRxiv.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.
Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union.
› Verified 6 days ago
Entity Name | Arkansas Health Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598031882 PECOS PAC ID: 7911802079 Enrollment ID: O20120611000172 |
News Archive
Researchers from the Duke Human Vaccine Institute and Duke University, Durham NC, USA, recently analyzed the D614G mutation in SARS-CoV-2 in the context of a soluble S ectodomain construct. Their study has been published in the preprint server bioRxiv.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.
Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Katie Beal, MD 500 N Keene St, Suite 400, Columbia, MO 65201-8104 Ph: () - | Katie Beal, MD 2900 Medical Center Pkwy Ste 240a, Bentonville, AR 72712-3204 Ph: (479) 553-3340 |
News Archive
Researchers from the Duke Human Vaccine Institute and Duke University, Durham NC, USA, recently analyzed the D614G mutation in SARS-CoV-2 in the context of a soluble S ectodomain construct. Their study has been published in the preprint server bioRxiv.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.
Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union.
› Verified 6 days ago
Audra Cole, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 Se 28th St Ste 2, Bentonville, AR 72712 Phone: 479-271-0005 Fax: 479-273-1427 | |
Dr. Lawrence Schmitz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 Se 28th St, Ste. 2, Bentonville, AR 72712 Phone: 479-271-0005 Fax: 479-273-1427 | |
Dr. James Todd Hannah, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1200 Se 28th St, Ste 2, Bentonville, AR 72712 Phone: 479-271-0005 Fax: 479-273-1427 | |
Dr. Lisa Ann Bearden, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy, Suite 370, Bentonville, AR 72712 Phone: 479-876-8111 Fax: 479-876-8110 | |
Amber June Sills, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy, Suite 370, Bentonville, AR 72712 Phone: 479-553-2525 | |
Dr. Amy M Fry, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy Ste 240a, Bentonville, AR 72712 Phone: 795-533-3340 Fax: 479-553-1964 |